This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Pancreatic Cancer Market

Market Insights on Pancreatic Cancer sales outlook, demand forecast & up-to-date key trends

Pancreatic Cancer Market by Treatment Type, Cancer Type, End User & Region – Forecast 2023–2033

Pancreatic Cancer Market Snapshot (2023-2033)

The global pancreatic cancer market will be valued at around US$ 2,125.57 Million in 2023. Market of Pancreatic Cancer are projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033.

Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role.

Data Points

Key Statistics

Anticipated Base Year Value (2022)

US$ 1,872.75 Million

Expected Market Value (2023)

US$ 2,125.57 Million

Projected Forecast Value (2033)

US$ 7,541.09 Million

Global Growth Rate (2023-2033)

13.5% CAGR

Expected Market Share of the U.S. Market (2033)

53%

Anticipated Market Value of Europe (2023-2033)

31%

Customize this Report

Let us know your requirement to get
100% FREE customization

Revenue Analysis of Pancreatic Cancer from 2018-2022 Vs Market Projections for 2023 to 2033

Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period.

The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.

Which are Some Prominent Drivers of Pancreatic Cancer Market?

Owing to the lack of therapeutic procedures for early diagnosis, the pancreatic cancer market is expanding in developed nations

The American Society of Clinical Oncology predicts that 62,210 adults in the United States will be diagnosed with pancreatic cancer in 2022. The high prevalence of pancreatic cancer, which causes germline mutations, is also predicted to boost overall growth.

Besides that, the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to the body's healthy peripheral cells. The industry is being influenced by the increasing prevalence of pancreatic cancer and the requirement for targeted therapy.

NCI funded research projects to empower the market to grow

The National Cancer Institute has sponsored several research programs dedicated to developing treatments and medications for pancreatic cancer. The Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Cancer Detection Consortium (PCDC), Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC), Pancreatic Cancer Microenvironment Network (PaCMEN), RAS Initiative, Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), and others are instances of financed projects.

These programs each have their mission and targets, and they each seek to find novel solutions to the ailment. The Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), for instance, is an intervention designed to quickly implement principal scientific discoveries into medical settings. The Pancreatic SPORE grants promote novel and diverse methods of prevention and treatment.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Pancreatic Cancer Market?

rising costs of drug development and treatment, along with strict regulatory guidelines to constrain market growth

The elevated cost of drug advancement and treatment may stifle future growth. During the projected timeframe, the market will also face obstacles from stringent government laws and regulations. Inventions and comprehensive authorization methods can assist in overcoming these challenges and propelling the global pancreatic cancer market forward.

Which Regional Market is the Most Profitable for Pancreatic Cancer Manufacturers?

In 2021, the North American pancreatic cancer market dominated the global market. This is because pancreatic cancer is more prevalent in North American countries, with the United States having the most cancer victims globally. As a consequence, North America possessed the leading revenue proportion in the pancreatic cancer treatment market in 2021. It is primarily owing to the upgraded healthcare system, widespread utilization of pancreatic treatment procedures, and a huge target citizenry. Furthermore, the increasing prevalence of pancreatic cancer is driving up requirements for treatment options.

The Asia-Pacific pancreatic cancer market is expected to be the most rapidly sprouting in the globe. Asia Pacific, as a result, hand, is projected to expand the fastest during the projected timeline. The existence of well-established clinics and critical care centers, as well as a massive population suffering from pancreatic cancer, would help the industry develop in the Asia Pacific region. Furthermore, with the increasing number of pancreatic cancer cases in Asia Pacific, pancreatic cancer diagnosis and treatment must abide by the same protocol as in Western nations.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Country-wise Analysis

Why Will United States Dominate Pancreatic Cancer Market in North America?

The rapid rise of pancreatic cancer patients and, increased investment in healthcare infrastructure propel the market

In North America, the United States of America leads the pancreatic cancer market. Based on the American Cancer Society's National Survey, approximately 3% of cancers in the United States were pancreatic by 2021. Moreover, pancreatic cancers account for 9% of all cancer deaths. The rising number of pancreatic cancer patients is accompanied by higher investment in medical infrastructure.

The simplification of regulatory approval processes has resulted in the safe and prompt approval of clinical drugs and treatments in the United States, contributing to the rising demand for pancreatic cancer treatment options in the country.

Which European Nation Will Emerge as Highest Share Holder?

Surging tobacco consumption levels will propel the market forward

Germany had the highest number of cases reported of pancreatic cancer in Europe in 2021, with 21,859 cases. Rising tobacco consumption rates and a boost in cigarette smokers are expected to boost the expansion of the pancreatic cancer market.

Furthermore, rising cancer prevalence, increased alcohol consumption, rising obesity rates, and increasing acceptance of various treatment options available are all forecasting overall growth in this country.

Country-wise Forecast CAGRs for the Pancreatic Cancer Industry

China

12%

U.S.

13.7%

Australia

10%

France

11%

Category-wise Insights

Which End-User Segment Will Hold the Largest Market Share?

Hospitals segment is dominant owing to the modern infrastructure

Based on end-user, the Hospital segment is the largest profit segment in the global pancreatic cancer therapeutics market, and this trend is expected to persist in the forecast years. The hospital segment is dominant owing to the quick influx of patients admitted to hospitals due to competent medical practitioners and the accessibility of multiple systems. In addition, hospitals have decent infrastructure and a wide network, which is cruising market growth. The hospital segment accounted for a 48% share of the market in 2022.

Which Treatment Type Segments Will lead the Industry Growth?

Surgery and radiology segments are expected to lead the industry

Because of the incidence of these methodologies, treatment-type segments such as surgery and radiology are likely to dominate the market throughout the forecast period.

The prominence of targeted drugs and unique biologic therapeutics can also be credited to this segment's supremacy. Furthermore, personalized treatment systems are assisting in the segment's advancement.

Start-ups operating in the Pancreatic Cancer Domain

  • Biosense was established in 2008. Biosense is a medical engineering and development company that produces ground-breaking diagnostics. Rexahn announced a contract with BioSense in April 2019 to commercialize its pancreatic cancer treatment in Greater China.
  • ElmediX was established in 2015 as a spin-off of the University of Antwerp with a single objective in mind: to produce a disruptive solution for (pancreatic) cancer and other life-threatening ailments. They produce oncothermia-based treatments for pancreatic cancer that minimize the likelihood of toxicity to healthy tissue.

Market Competition            

Key players in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics.

  • In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.
  • As per Oncolytics Biotech® Inc., the FDA approved pelareorep in December 2022 in conjunction with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, the chemotherapeutic agent's drugs gemcitabine and nab-paclitaxel for the diagnosis of advanced or metastatic pancreatic ductal adenocarcinoma (TSX: ONC).

Report Scope

Report Attribute

Details

Expected Market Value (2023)

US$ 2,125.57 Million

Projected Forecast Value (2033)

US$ 7,541.09 Million

Global Growth Rate (2023-2033)

13.5% CAGR

Base Year for Estimation

2022

Historical Data

2018-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in USD Million and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Treatment Type
  • Cancer Type
  • End Use
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Pfizer Inc.
  • Novartis AG
  • Eli Lily and Company
  • Bristol Myers Squibb Company
  • Zydus Cadila
  • Myriad Genetics Inc.
  • F-Hoffmann-La Roche Ltd.
  • PharmaCyte Biotech Inc.
  • Teva Pharmaceutical Industries Ltd.

Customization

Available Upon Request

Key Segments Profiled in the Pancreatic Cancer Industry Survey

By Treatment Type:

  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Surgery
  • Radiation Therapy
  • Targeted Drug Therapy
  • Others

By Cancer Type:

  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Research Laboratories
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

As of 2022, the Pancreatic Cancer market was worth US$ 73.75 Million

Fact.MR foresees Pancreatic Cancer demand to reach US$ 2125.57 Million in 2023

From 2023-2033, Fact.MR expects Pancreatic Cancer revenue to flourish at a 13.5% CAGR

In 2033, Pancreatic Cancer market worth is poised to reach US$ 7541.09 Million

North American regional market is expected to rise 1.4X by 2033.

U.S. is expected to possess 35% market share for Pancreatic Cancer in 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2023-2033

        5.3.1. Chemotherapy

        5.3.2. Immunotherapy

        5.3.3. Hormone Therapy

        5.3.4. Surgery

        5.3.5. Radiation Therapy

        5.3.6. Targeted Drug Therapy

        5.3.7. Others

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Cancer Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Cancer Type, 2018-2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Cancer Type, 2023-2033

    6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User , 2018-2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User , 2023-2033

        7.3.1. Hospitals

        7.3.2. Clinics

        7.3.3. Diagnostic Laboratories

        7.3.4. Research Institutes

        7.3.5. Research Laboratories

        7.3.6. Others

    7.4. Y-o-Y Growth Trend Analysis By End User , 2018-2022

    7.5. Absolute $ Opportunity Analysis By End User , 2023-2033

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Treatment Type

        9.2.3. By Cancer Type

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Type

        9.3.3. By Cancer Type

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment Type

        10.2.3. By Cancer Type

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By Cancer Type

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment Type

        11.2.3. By Cancer Type

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Cancer Type

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Treatment Type

        12.2.3. By Cancer Type

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Cancer Type

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Treatment Type

        13.2.3. By Cancer Type

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Cancer Type

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Treatment Type

            14.1.2.2. By Cancer Type

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Treatment Type

            14.2.2.2. By Cancer Type

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Treatment Type

            14.3.2.2. By Cancer Type

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Treatment Type

            14.4.2.2. By Cancer Type

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Treatment Type

            14.5.2.2. By Cancer Type

            14.5.2.3. By End User

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Treatment Type

            14.6.2.2. By Cancer Type

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Treatment Type

            14.7.2.2. By Cancer Type

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Treatment Type

            14.8.2.2. By Cancer Type

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Treatment Type

            14.9.2.2. By Cancer Type

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Treatment Type

            14.10.2.2. By Cancer Type

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Treatment Type

            14.11.2.2. By Cancer Type

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Treatment Type

            14.12.2.2. By Cancer Type

            14.12.2.3. By End User

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Treatment Type

            14.13.2.2. By Cancer Type

            14.13.2.3. By End User

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Treatment Type

            14.14.2.2. By Cancer Type

            14.14.2.3. By End User

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Treatment Type

            14.15.2.2. By Cancer Type

            14.15.2.3. By End User

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Treatment Type

            14.16.2.2. By Cancer Type

            14.16.2.3. By End User

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Treatment Type

            14.17.2.2. By Cancer Type

            14.17.2.3. By End User

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Treatment Type

            14.18.2.2. By Cancer Type

            14.18.2.3. By End User

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Treatment Type

            14.19.2.2. By Cancer Type

            14.19.2.3. By End User

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Treatment Type

            14.20.2.2. By Cancer Type

            14.20.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Treatment Type

        15.3.3. By Cancer Type

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Pfizer Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Novartis AG

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Eli Lilly and Company

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Bristol Myers Squibb Company

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Zydus Cadila

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. AstraZeneca PLC

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Myriad Genetics Inc.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. F Hoffmann-La Roche Ltd.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. PharmaCyte Biotech Inc.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Teva Pharmaceutical Industries Ltd.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 3: Global Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 4: Global Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 6: North America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 7: North America Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 8: North America Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 10: Latin America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 11: Latin America Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 12: Latin America Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 14: Europe Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 15: Europe Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 16: Europe Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 20: Asia Pacific Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 22: MEA Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033

Table 23: MEA Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033

Table 24: MEA Market Value (US$ Mn) Forecast by End User , 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 3: Global Market Value (US$ Mn) by End User , 2023-2033

Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 8: Global Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 11: Global Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 14: Global Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 17: Global Market Attractiveness by Treatment Type, 2023-2033

Figure 18: Global Market Attractiveness by Cancer Type, 2023-2033

Figure 19: Global Market Attractiveness by End User , 2023-2033

Figure 20: Global Market Attractiveness by Region, 2023-2033

Figure 21: North America Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 22: North America Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 23: North America Market Value (US$ Mn) by End User , 2023-2033

Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 28: North America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 31: North America Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 34: North America Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 37: North America Market Attractiveness by Treatment Type, 2023-2033

Figure 38: North America Market Attractiveness by Cancer Type, 2023-2033

Figure 39: North America Market Attractiveness by End User , 2023-2033

Figure 40: North America Market Attractiveness by Country, 2023-2033

Figure 41: Latin America Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 42: Latin America Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 43: Latin America Market Value (US$ Mn) by End User , 2023-2033

Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 48: Latin America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 51: Latin America Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 54: Latin America Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 57: Latin America Market Attractiveness by Treatment Type, 2023-2033

Figure 58: Latin America Market Attractiveness by Cancer Type, 2023-2033

Figure 59: Latin America Market Attractiveness by End User , 2023-2033

Figure 60: Latin America Market Attractiveness by Country, 2023-2033

Figure 61: Europe Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 62: Europe Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 63: Europe Market Value (US$ Mn) by End User , 2023-2033

Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 68: Europe Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 71: Europe Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 74: Europe Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 77: Europe Market Attractiveness by Treatment Type, 2023-2033

Figure 78: Europe Market Attractiveness by Cancer Type, 2023-2033

Figure 79: Europe Market Attractiveness by End User , 2023-2033

Figure 80: Europe Market Attractiveness by Country, 2023-2033

Figure 81: Asia Pacific Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 82: Asia Pacific Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 83: Asia Pacific Market Value (US$ Mn) by End User , 2023-2033

Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023-2033

Figure 98: Asia Pacific Market Attractiveness by Cancer Type, 2023-2033

Figure 99: Asia Pacific Market Attractiveness by End User , 2023-2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023-2033

Figure 101: MEA Market Value (US$ Mn) by Treatment Type, 2023-2033

Figure 102: MEA Market Value (US$ Mn) by Cancer Type, 2023-2033

Figure 103: MEA Market Value (US$ Mn) by End User , 2023-2033

Figure 104: MEA Market Value (US$ Mn) by Country, 2023-2033

Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 108: MEA Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033

Figure 109: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033

Figure 111: MEA Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033

Figure 112: MEA Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033

Figure 114: MEA Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 115: MEA Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 117: MEA Market Attractiveness by Treatment Type, 2023-2033

Figure 118: MEA Market Attractiveness by Cancer Type, 2023-2033

Figure 119: MEA Market Attractiveness by End User , 2023-2033

Figure 120: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Pancreatic Elastase Testing Market

Published : October 2021

Healthcare

Pancreatic Stone Protein Testing Market

Published : October 2019

Healthcare

Cancer Antigens Market

Published : October 2019

Healthcare

Pancreatic Cyst Diagnostics Market

Published : June 2019

Google translate

Pancreatic Cancer Market